NO301832B1 - Fremgangsmåte for fremstilling av en isoform av erythropoietin - Google Patents
Fremgangsmåte for fremstilling av en isoform av erythropoietin Download PDFInfo
- Publication number
- NO301832B1 NO301832B1 NO912281A NO912281A NO301832B1 NO 301832 B1 NO301832 B1 NO 301832B1 NO 912281 A NO912281 A NO 912281A NO 912281 A NO912281 A NO 912281A NO 301832 B1 NO301832 B1 NO 301832B1
- Authority
- NO
- Norway
- Prior art keywords
- erythropoietin
- isoforms
- isoform
- gel
- column
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 172
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 161
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 160
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 157
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 157
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 146
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 31
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 30
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract description 14
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims abstract description 14
- 102000044890 human EPO Human genes 0.000 claims abstract description 14
- 108091029865 Exogenous DNA Proteins 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 125000005629 sialic acid group Chemical group 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 17
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000001155 isoelectric focusing Methods 0.000 abstract description 37
- 108010092408 Eosinophil Peroxidase Proteins 0.000 abstract description 19
- 102100031939 Erythropoietin Human genes 0.000 abstract description 19
- 150000001413 amino acids Chemical class 0.000 abstract description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 66
- 239000000499 gel Substances 0.000 description 43
- 230000000694 effects Effects 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 33
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 238000001727 in vivo Methods 0.000 description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 239000000872 buffer Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000002482 oligosaccharides Polymers 0.000 description 17
- 239000004202 carbamide Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000012614 Q-Sepharose Substances 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 10
- 238000003127 radioimmunoassay Methods 0.000 description 10
- 238000009010 Bradford assay Methods 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000581 polycythemic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100084404 Mus musculus Prodh gene Proteins 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000959 ampholyte mixture Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 108010027485 asialoerythropoietin Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108010057760 hepatic sialoglycoprotein receptor Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- -1 urine-derived Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42144489A | 1989-10-13 | 1989-10-13 | |
PCT/US1990/005758 WO1991005867A1 (en) | 1989-10-13 | 1990-10-09 | Erythropoietin isoforms |
Publications (3)
Publication Number | Publication Date |
---|---|
NO912281L NO912281L (no) | 1991-06-13 |
NO912281D0 NO912281D0 (no) | 1991-06-13 |
NO301832B1 true NO301832B1 (no) | 1997-12-15 |
Family
ID=23670537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO912281A NO301832B1 (no) | 1989-10-13 | 1991-06-13 | Fremgangsmåte for fremstilling av en isoform av erythropoietin |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP0428267B2 (pt) |
JP (2) | JP2983629B2 (pt) |
KR (2) | KR100221066B1 (pt) |
CN (1) | CN1063796C (pt) |
AT (2) | ATE184914T1 (pt) |
AU (1) | AU646822B2 (pt) |
CA (2) | CA2165694C (pt) |
CZ (4) | CZ291515B6 (pt) |
DE (2) | DE69033301T2 (pt) |
DK (2) | DK0428267T4 (pt) |
ES (2) | ES2139764T3 (pt) |
FI (1) | FI105688B (pt) |
GR (2) | GR3022658T3 (pt) |
HK (2) | HK1006718A1 (pt) |
IE (1) | IE903663A1 (pt) |
IL (3) | IL125175A (pt) |
LV (1) | LV12575B (pt) |
NO (1) | NO301832B1 (pt) |
NZ (1) | NZ235676A (pt) |
PT (1) | PT95586B (pt) |
SK (1) | SK284429B6 (pt) |
WO (1) | WO1991005867A1 (pt) |
ZA (1) | ZA908166B (pt) |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
AU6709794A (en) * | 1993-04-21 | 1994-11-08 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
ZA946122B (en) * | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5696250A (en) | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
JP4410852B2 (ja) | 1996-08-02 | 2010-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 単一の共有結合n末端水溶性ポリマーを有するポリペプチド |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
IL124015A0 (en) | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
EP1071795A4 (en) | 1998-04-22 | 2005-01-19 | Cornell Res Foundation Inc | CANINE ERITHROPOIETINE GENE AND RECOMBINANT PROTEIN |
ATE339507T1 (de) | 1998-06-15 | 2006-10-15 | Gtc Biotherapeutics Inc | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
DE69935345T3 (de) * | 1998-10-23 | 2018-03-01 | Amgen Inc. | Methoden und zusammensetzungen zur prävention und behandlung der anämie |
BR9905868A (pt) * | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento |
AU2346900A (en) * | 1998-11-30 | 2000-06-19 | Eli Lilly And Company | Erythropoietic compounds |
WO2003038100A1 (en) | 2001-10-29 | 2003-05-08 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
MXPA02007733A (es) | 2000-02-11 | 2004-09-10 | Merck Patent Gmbh | Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos. |
CA2406807C (en) | 2000-04-21 | 2010-04-06 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US7645898B2 (en) | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
EP1366067B1 (en) | 2001-03-07 | 2012-09-26 | Merck Patent GmbH | Expression technology for proteins containing a hybrid isotype antibody moiety |
US7332289B2 (en) | 2001-03-09 | 2008-02-19 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US7531358B2 (en) | 2001-04-17 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying surfactant |
PL205352B1 (pl) | 2001-05-03 | 2010-04-30 | Merck Patent Gmbh | Rekombinowane przeciwciało specyficzne dla nowotworu |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
BR0312395A (pt) * | 2002-07-01 | 2007-06-19 | Kenneth S Warren Inst Inc | citocina protetora de tecido recombinante de muteìna, célula de mamìfero responsiva à citocina protetora de tecido recombinante, molécula de ácido nucleico isolada, vetor, vetor de expressão, célula geneticamente engenheirada, célula, composição farmacêutica, método para proteger, manter ou realçar a viabilidade de uma célula, tecido ou órgão isolados de um corpo de mamìfero, uso de uma citocina protetora de tecido recombinante, método para facilitar a transcitose de uma molécula através de uma barreira de célula endotelial em um mamìfero, e, composição para transportar uma molécula por intermédio da transcitose através de uma barreira de célula endotelial |
EP1541165A4 (en) | 2002-08-27 | 2009-06-24 | Chugai Pharmaceutical Co Ltd | METHOD FOR STABILIZING PROTEIN PREPARATION |
DE20321793U1 (de) | 2002-09-11 | 2010-06-02 | Fresenius Kabi Deutschland Gmbh | Hydroxyalkylstärke-Derivate |
EP3225625A1 (en) | 2002-09-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
AU2003260393B2 (en) | 2002-09-11 | 2009-10-01 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
WO2004032971A1 (en) | 2002-10-08 | 2004-04-22 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
CA2539440A1 (en) | 2003-09-29 | 2005-04-14 | Warren Pharmaceuticals, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
MXPA06009072A (es) | 2004-02-09 | 2007-03-29 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
KR101186821B1 (ko) | 2004-03-11 | 2012-09-28 | 프레제니우스 카비 도이치란트 게엠베하 | 환원성 아미노화에 의해 제조된, 하이드록시알킬 녹말 및단백질의 접합체 |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
EP1848461A2 (en) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
AU2006285026B2 (en) | 2005-08-31 | 2012-08-09 | University Of Tennessee Research Foundation | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
ES2913277T3 (es) | 2005-12-08 | 2022-06-01 | Amgen Inc | Producción mejorada de glicoproteínas utilizando manganeso |
CA2630782C (en) | 2005-12-08 | 2015-02-03 | Amgen Inc. | Improved host cells and culture methods |
WO2007083683A1 (ja) * | 2006-01-18 | 2007-07-26 | Chugai Seiyaku Kabushiki Kaisha | シアル酸の除去方法及びアシアロエリスロポエチンの製造方法 |
JP5553506B2 (ja) | 2006-03-22 | 2014-07-16 | 中外製薬株式会社 | エリスロポエチン溶液製剤 |
BRPI0712063A2 (pt) | 2006-06-07 | 2011-12-20 | Chugai Pharmaceutical Co Ltd | tratamento de doenças isquêmicas usando eritropoietina |
PL2038252T3 (pl) | 2006-07-12 | 2017-03-31 | University Of Tennessee Research Foundation | Podstawione acyloanilidy i sposoby ich zastosowania |
AU2007275638B2 (en) | 2006-07-21 | 2014-01-16 | Amgen Inc. | Method of detecting and/ or measuring hepcidin in a sample |
CN101511391B (zh) | 2006-07-25 | 2013-03-13 | 利普生技术有限公司 | N末端聚唾液酸化 |
WO2008023725A1 (fr) | 2006-08-22 | 2008-02-28 | Chugai Seiyaku Kabushiki Kaisha | Agent préventif et/ou thérapeutique pour une neuropathie périphérique |
MX2009001962A (es) | 2006-08-24 | 2009-04-30 | Univ Tennessee Res Foundation | Acilanilidas substituidas y metodos de uso de las mismas. |
DK2081956T3 (da) | 2006-11-13 | 2013-06-24 | Charite Universitaetsmedizin | FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT |
AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
US9175078B2 (en) | 2008-01-25 | 2015-11-03 | Amgen Inc. | Ferroportin antibodies and methods of use |
CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
DE102008002209A1 (de) | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Aufreinigung von Erythropoietin |
US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
EP2161031A1 (en) | 2008-09-05 | 2010-03-10 | SuppreMol GmbH | Fc gamma receptor for the treatment of B cell mediated multiple sclerosis |
WO2010034442A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
CN104922669A (zh) | 2008-11-13 | 2015-09-23 | 通用医疗公司 | 用于通过调整bmp-6来调节铁稳态的方法和组合物 |
DE102008054716A1 (de) | 2008-12-16 | 2010-06-17 | Evonik Degussa Gmbh | Inprozesskontrolle in einem Verfahren zur Herstellung von EPO |
WO2011011674A2 (en) | 2009-07-24 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Production of erythropoiesis stimulating protein using metal ions |
EP2480569B1 (en) | 2009-09-23 | 2016-04-13 | ratiopharm GmbH | Process for the purification of recombinant human erythropoietin (epo) |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
KR20180037303A (ko) | 2010-06-07 | 2018-04-11 | 암젠 인크 | 약물 전달 장치 |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
TR201908439T4 (tr) | 2011-10-14 | 2019-07-22 | Amgen Inc | Enjektör ve montaj yöntemi. |
US20150065689A1 (en) * | 2012-04-10 | 2015-03-05 | Dr. Reddy's Laboratories Limited | Single step fractionation method |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
CN108143728A (zh) | 2012-07-13 | 2018-06-12 | Gtx公司 | 选择性雄激素受体调节剂在治疗乳癌中的用途 |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
EP3072548B1 (en) | 2012-11-21 | 2019-03-06 | Amgen, Inc | Drug delivery device |
ES2730690T3 (es) | 2012-12-07 | 2019-11-12 | Suppremol Gmbh | Estratificación y tratamiento de pacientes que padecen púrpura trombocitopénica idiopática |
EP2968736A4 (en) | 2013-03-15 | 2016-11-09 | Amgen Inc | ADJUSTABLE TO A BODY SHAPE AUTO INJECTOR DEVICE |
EP3593839A1 (en) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Drug cassette |
CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
CN110041427B (zh) | 2013-03-15 | 2023-05-23 | 本质生命科学有限公司 | 抗铁调素抗体及其用途 |
US10850037B2 (en) | 2013-03-22 | 2020-12-01 | Amgen Inc. | Injector and method of assembly |
MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
MX2016005312A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Inyector y metodo de montaje. |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
US10188739B2 (en) | 2014-02-27 | 2019-01-29 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
MX2016015467A (es) | 2014-05-30 | 2017-03-23 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. |
US20170124285A1 (en) | 2014-06-03 | 2017-05-04 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
WO2016100781A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with proximity sensor |
EP3689394A1 (en) | 2014-12-19 | 2020-08-05 | Amgen Inc. | Drug delivery device with live button or user interface field |
MX2017010466A (es) | 2015-02-17 | 2018-06-06 | Amgen Inc | Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas. |
WO2016138434A1 (en) | 2015-02-27 | 2016-09-01 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
EP3582829A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Insertion mechanism for drug delivery device |
AU2018231107B2 (en) | 2017-03-06 | 2023-04-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
SG11201908058UA (en) | 2017-03-07 | 2019-09-27 | Amgen Inc | Needle insertion by overpressure |
CA3052310A1 (en) | 2017-03-09 | 2018-09-13 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
FI3600491T3 (fi) | 2017-03-28 | 2023-10-20 | Amgen Inc | Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
EP4292576A3 (en) | 2017-07-21 | 2024-01-17 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
MA49677A (fr) | 2017-07-25 | 2021-04-21 | Amgen Inc | Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
ES2971450T3 (es) | 2017-10-06 | 2024-06-05 | Amgen Inc | Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
EP3710089A1 (en) | 2017-11-16 | 2020-09-23 | Amgen Inc. | Autoinjector with stall and end point detection |
SG11202003004RA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Door latch mechanism for drug delivery device |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
US12042645B2 (en) | 2018-07-24 | 2024-07-23 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
AU2019347710A1 (en) | 2018-09-24 | 2021-02-04 | Amgen Inc. | Interventional dosing systems and methods |
IL281469B2 (en) | 2018-09-28 | 2024-08-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
CN112805048B (zh) | 2018-10-02 | 2023-09-22 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
MX2021003491A (es) | 2018-10-05 | 2021-06-18 | Amgen Inc | Dispositivo de administracion de farmacos con indicador de dosis. |
WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
CA3112355A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
WO2020091981A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
WO2020219482A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
CU24704B1 (es) * | 2019-09-05 | 2024-04-08 | Ct Inmunologia Molecular | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
WO2023209074A1 (en) | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2354793A1 (fr) * | 1976-06-14 | 1978-01-13 | Gresset Bernard | Jouet tel que tableau |
FR2475988A2 (fr) * | 1978-09-04 | 1981-08-21 | Cassagnes Andre | Appareil a dessiner |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
-
1990
- 1990-10-09 KR KR1019910700600A patent/KR100221066B1/ko not_active IP Right Cessation
- 1990-10-09 KR KR1019980707104A patent/KR100263845B1/ko not_active IP Right Cessation
- 1990-10-09 WO PCT/US1990/005758 patent/WO1991005867A1/en active IP Right Grant
- 1990-10-09 AU AU66042/90A patent/AU646822B2/en not_active Expired
- 1990-10-09 JP JP2514568A patent/JP2983629B2/ja not_active Expired - Lifetime
- 1990-10-12 ES ES95101849T patent/ES2139764T3/es not_active Expired - Lifetime
- 1990-10-12 IL IL12517590A patent/IL125175A/en not_active IP Right Cessation
- 1990-10-12 NZ NZ235676A patent/NZ235676A/en unknown
- 1990-10-12 AT AT95101849T patent/ATE184914T1/de not_active IP Right Cessation
- 1990-10-12 ZA ZA908166A patent/ZA908166B/xx unknown
- 1990-10-12 DE DE69033301T patent/DE69033301T2/de not_active Expired - Lifetime
- 1990-10-12 SK SK4972-90A patent/SK284429B6/sk not_active IP Right Cessation
- 1990-10-12 EP EP90311193A patent/EP0428267B2/en not_active Expired - Lifetime
- 1990-10-12 CN CN90109447A patent/CN1063796C/zh not_active Expired - Lifetime
- 1990-10-12 DK DK90311193T patent/DK0428267T4/da active
- 1990-10-12 IE IE366390A patent/IE903663A1/en not_active IP Right Cessation
- 1990-10-12 AT AT90311193T patent/ATE146187T1/de not_active IP Right Cessation
- 1990-10-12 EP EP95101849A patent/EP0668351B1/en not_active Expired - Lifetime
- 1990-10-12 IL IL95971A patent/IL95971A0/xx not_active IP Right Cessation
- 1990-10-12 DK DK95101849T patent/DK0668351T3/da active
- 1990-10-12 PT PT95586A patent/PT95586B/pt not_active IP Right Cessation
- 1990-10-12 CZ CZ19904972A patent/CZ291515B6/cs not_active IP Right Cessation
- 1990-10-12 DE DE69029370T patent/DE69029370C5/de not_active Expired - Lifetime
- 1990-10-12 ES ES90311193T patent/ES2097753T5/es not_active Expired - Lifetime
- 1990-10-15 CA CA002165694A patent/CA2165694C/en not_active Expired - Lifetime
- 1990-10-15 CA CA002027635A patent/CA2027635C/en not_active Expired - Lifetime
-
1991
- 1991-06-12 FI FI912829A patent/FI105688B/fi active
- 1991-06-13 NO NO912281A patent/NO301832B1/no not_active IP Right Cessation
-
1995
- 1995-03-16 JP JP07057432A patent/JP3073905B2/ja not_active Expired - Lifetime
-
1997
- 1997-02-26 GR GR970400345T patent/GR3022658T3/el unknown
-
1998
- 1998-06-23 HK HK98106060A patent/HK1006718A1/xx not_active IP Right Cessation
- 1998-07-01 IL IL12517598A patent/IL125175A0/xx active IP Right Grant
- 1998-10-20 HK HK98111344A patent/HK1010398A1/xx not_active IP Right Cessation
-
1999
- 1999-12-08 GR GR990403180T patent/GR3032089T3/el unknown
-
2000
- 2000-05-04 LV LVP-00-60A patent/LV12575B/en unknown
- 2000-05-12 CZ CZ20001772A patent/CZ291488B6/cs not_active IP Right Cessation
-
2001
- 2001-03-27 CZ CZ20011115A patent/CZ291471B6/cs not_active IP Right Cessation
- 2001-03-27 CZ CZ20011117A patent/CZ291472B6/cs not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO301832B1 (no) | Fremgangsmåte for fremstilling av en isoform av erythropoietin | |
US5856298A (en) | Erythropoietin isoforms | |
RU2159814C2 (ru) | Аналог эритропоэтина | |
US7217689B1 (en) | Glycosylation analogs of erythropoietin | |
CA2736141A1 (en) | Purification of erythropoietin | |
EP0902085A1 (en) | Recombinant human erythropoietin with advantageous glycosylation profile | |
CN101337988B (zh) | 一种新的促红细胞生成素类似物 | |
DE69022901T2 (de) | Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung. | |
CN103113464B (zh) | 天然人促红细胞生成素类似物 | |
EP0322084A2 (en) | Tumor cell inhibition factor | |
FI106563B (fi) | Menetelmä ihmisen erytropoietiinin analogien valmistamiseksi ja niitä koodittavat DNA-sekvenssit | |
Shoyab et al. | Amphiregulin-associated protein: complete amino acid sequence of a protein produced by the 12-0-tetradecanoylphorbol-13-acetate-treated human breast adenocarcinoma cell line MCF-7 | |
CN103073631A (zh) | 一种促红细胞生成素类似物 | |
WO1994025481A1 (en) | Method of separating glycosylated and non-glycosylated proteins | |
IE83805B1 (en) | Erythropoietin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |